Global Down Syndrome

Spring 2015

Issue link: https://viewer.e-digitaledition.com/i/518721

Contents of this Issue

Navigation

Page 9 of 31

CONTINUED FROM PAGE 8 syndrome divide and proliferate in the hopes that it could shed light on why these cells are less prone to forming tumors. THE LEUKEMIA PARADOX Children with Down syndrome have a 10- to 20-fold higher risk of developing leukemia than typical children, and one study estimated that children with Down syndrome have a 500-fold higher risk than typical children of developing a rare form of the disease called acute megakaryocytic leukemia (AMkL). Remarkably, however, children with Down syndrome and AMkL have a significantly better prognosis for treatment. These children are considered the disease's most treatable subgroup, with a cure rate of 80 to 85 percent, while the prognosis for typical children with AMkL is considered to be very poor. "I've been working in this field for 15 years, and we still don't know the link between Down syndrome and leukemia," said John Crispino, Ph.D., Robert I. Lurie, M.D., and Lora S. Lurie Professor of Medicine in Hematology/ Oncology and Biochemistry and Molecular Genetics at Northwestern University School of Medicine. "But there is a great deal of research going on in this area." Dr. Crispino is particularly focused on the links between AMkL and transient leukemia, which may be present at birth in infants with Down syndrome. In most cases, the condition goes away on its own, but in 10 to 20 percent of children with Down syndrome, it develops into AMkL. Some of his recent studies have identified specific genetic mutations that may be involved in the transition from one form of the cancer to another. For example, mutations on the GATA1 gene, which affect the development of red blood cells and megakaryocytes (cells found in bone marrow that form blood platelets), are found uniformly in children with Down syndrome whose transient leukemia develops into AMkL. He's also focused on a specific gene called ERG, which promotes the growth of AMkL. "It's thought that overexpression of ERG due to the extra copy of chromosome 21 leads to leukemia," Dr. Crispino said. "We and others have found that overexpression is necessary, but it's likely that a combination of chromosome 21 genes drives leukemia development." The ultimate goal, he added, is to find out why these children get the condition and what it is about their genetic code that makes them more responsive to treatment. "I am very close to a family whose son has Down syndrome and leukemia," Dr. Crispino said. "During his three-year course of chemotherapy, he suffered so many side effects. It was heartbreaking to hear what he had to go through to get treatment. We need better therapies for children with Down syndrome and for all children with leukemia." "To the average person, Down syndrome and cancer may seem unrelated," Dr. Espinosa said. "But scientists investigating the mechanisms by which individuals with Down syndrome are protected from or affected by cancer may illuminate fundamental biological principles of the syndrome and advance our ability to improve their lives." SCIENCE SNPS ONGOING CHALLENGES IN PRENATAL TESTING Noninvasive prenatal screening tests (NIPTs) are a relatively new tool for providing prenatal screening for chromosomal conditons such as Down syndrome. NIPTs gather fetal DNA from placental cells that have broken down and are circulating in the mother's bloodstream. A new survey of data from 90,000 cases shows that although NIPTs pose fewer fetal health risks than more invasive tests that are diagnostic, NIPTs are much less sensitive and yield a lower detection rate for Down syndrome. This study's results support the position of the American Congress of Obstetricians and Gynecologists, which states that NIPTs should be used for high-risk pregnancies but should not replace more accurate diagnostic tests, such as chorionic villus sampling or amniocentesis. Fetal Diagnosis and Therapy, January 2015 FAMILY + FOOD = HEALTHIER HABITS People with Down syndrome are more likely to be overweight or obese. Researchers examined nutritional intake in people with Down syndrome to better understand their eating habits and made an unexpected discovery: People with Down syndrome whose primary caretakers were family members had healthier diets than those with unrelated caretakers. Furthermore, while the former were more involved in selecting and preparing their own foods, people with unrelated caretakers frequently consumed soft drinks and precooked meals. This may indicate a need for more nutritional education and guidance for those living independently of family. Food & Nutrition Research, February 2015 COGNITION AND CHLORIDE FLUX A new study from Laura Cancedda, Ph.D., and her team at the Istituto Italiano di Tecnologia, Genova, Italy, revealed a new molecular mechanism that may be exploited to improve memory in people with Down syndrome. Looking at mice with Down syndrome-like cells, they found that neurons involved in memory and learning accumulate high levels of chloride ions relative to typical mice. A separate analysis of postmortem brain samples from people with Down syndrome revealed that they also accumulate higher levels of chloride inside these neurons. The researchers then treated the mice with an FDA-approved drug, bumetanide, which blocks the transport of chloride ions into cells and found that bumetanide treatment rescued memory deficits in Down syndrome mice. This study may lead to clinical trials of the drug in people with Down syndrome. Nature Medicine, April 2015 John Crispino, Ph.D., molecular biologist, with Jacob To learn more about the research being done at the Crnic Institute and around the world, visit globaldownsyndrome.org/crnicgrants. SPRING2015 DOWN SYNDROME WORLD 10

Articles in this issue

Links on this page

Archives of this issue

view archives of Global Down Syndrome - Spring 2015